Drug Approval | April 14, 2025
Aurobindo receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg
The product will be launched in Q1FY26
The product will be launched in Q1FY26
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
The supply of these goods is set to commence within the first quarter of FY26
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Strengthening capabilities in Peptide Therapeutics and CDMO services
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Subscribe To Our Newsletter & Stay Updated
